Patients Stopping Anti-Obesity Injections Gain Back Weight Far More Rapidly Than People Using Diet and Exercise

Fresh analysis indicates that patients who come off new GLP-1 drugs like Wegovy and Mounjaro tend to recover reduced body mass far faster than those who end conventional diet and exercise regimens.

Findings released in a leading medical journal demonstrates that while obese individuals frequently drop substantial amounts of their body weight while on the medication, the mass is regained at an estimated rate of 0.8 kg per month after stopping.

"Users buying these medications must be aware of the potential of fast rebound weight gain when the therapy concludes," stated researcher Dr. Susan Jebb.

Such speed of recovery means a return to starting weight in about 18 months.

Weighing Approaches

The research, which looked at 37 of studies involving over 9,000 of participants, contrasted the results of GLP-1 agonists with other pills.

Researchers emphasize that people who shed pounds through lifestyle changes alone generally have a less rapid weight regain—around 100 grams monthly—once they finish.

Understanding the Fast Regain

Doctors propose the way of the drugs is key to understanding the accelerated rebound.

These medications imitate a natural hormone called glucagon-like peptide-1, which helps regulate hunger.

"Artificially providing the hormone levels far above than the body's typical production might result in the body to generate a reduced amount of its own natural GLP-1, and may also reduce responsiveness to its effects," noted Dr. Adam Collins, a dietetics specialist.

"Stopping of this GLP-1 'fix' results in appetite is no longer kept in check, making binge eating much more probable."

An Ongoing Condition?

The NHS recommend the jabs for people with obesity-related health risks, alongside recommended diet and exercise modifications.

Many experts contend that, given the high risk of relapse, the therapy should be considered life-long.

This perspective is supported by drug manufacturers, who note that the results "highlight the long-term character of obesity," akin to managing diseases like high blood pressure.

User Accounts

Individuals who have come off the jabs describe a powerful resurgence of appetite.

"I experienced a trigger flipping and you become extremely hungry," said an individual.

This challenge is worsened if users have not developed permanent dietary or behavioural modifications during treatment.

Growing Adoption

Survey data show that millions of people in the UK have tried weight-loss jabs in the last 12 months, with interest remaining high.

• Use is more common among females compared to men.
• The middle-aged age group shows the highest level of interest.
• A large proportion obtain the drugs through private healthcare rather than public health services.

Ultimately, experts emphasize that while GLP-1 drugs are effective agents for shedding pounds, they are not a permanent solution and maintained weight loss relies on combined lifestyle support.